# A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

> **NCT05705271** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 200 (actual)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY94-8862)

## Key facts

- **NCT ID:** NCT05705271
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-08
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705271, "A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05705271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*